Cartesian Therapeutics, Inc.
RNACCartesian Therapeutics, Inc. in brief
Cartesian Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2007. Its market value was $192 M on 27 October 2026, which makes it the 16,359th largest listed company in the world and the 3,167th largest in the USA on this site. It employs about 58 people. Its largest business segments by sales in 2025 were Operating (100%). Its shares trade under the symbol RNAC (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Cartesian Therapeutics, Inc.
Selecta Biosciences is a Biopharmaceutical and Gene Therapy company wholly owned, proprietary pipeline and work with partners with the goal of addressing immunogenicity to create life changing therapies for patients and their families. The company annual revenue is 27.6 million USD and 39 employees as on 2019. The headquarters is in USA.
Cartesian Therapeutics, Inc. timeline
- 2007
- 🏁· approximateFounded
- 2009
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- 🔔· approximateInitial public offering on Nasdaq
- 2022
- 💰Record revenue of $111 millionFY2022, the highest of the 7 years on record.
- 2023
- ✎Renamed Cartesian Therapeutics, Inc.Formerly Selecta Biosciences Inc.
Events of Cartesian Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,209 (Jan 2020) · #2,890 (Jan 2021) · #3,336 (Jan 2022) · #3,948 (Dec 2022) · #3,780 (Jul 2023) · #3,482 (Jan 2024) · #3,122 (Oct 2026) · #3,184 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -41.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 142.6%
- Net debt
- $-125M
- Revenue growth
- +49.7%
- R&D / revenue
- 115.9%
- Profit per employee
- $-2.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-143M | $-130M | — |
| Dec 2024 | $39M | +49.7% | $-44M | $-77M | -199.0% |
| Dec 2023 | $26M | -76.5% | $-86M | $-220M | -845.0% |
| Dec 2022 | $111M | +30.2% | $15M | $35M | 31.9% |
| Dec 2021 | $85M | +412.5% | $-5M | $-26M | -30.2% |
| Dec 2020 | $17M | +148.5% | $-57M | $-69M | -414.9% |
| Dec 2019 | $7M | +642.2% | $-52M | $-55M | -828.6% |
| Dec 2018 | $1M | — | $-65M | $-65M | -7260.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-74M | $5M | $-79M | $-5.02 | — |
| Dec 2024 | $-24M | $9M | $-33M | $-4.49 | — |
| Dec 2023 | $-51M | $0M | $-51M | $-49.76 | — |
| Dec 2022 | $-32M | $1M | $-33M | $0.10 | — |
| Dec 2021 | $-60M | $1M | $-61M | $-0.22 | — |
| Dec 2020 | $35M | $1M | $34M | $-0.68 | — |
| Dec 2019 | $-51M | $0M | $-51M | $-1.22 | — |
| Dec 2018 | $-59M | $1M | $-60M | $-2.92 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Sep 29, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 17, 20268-KCurrent reportShareholder vote
- Jun 9, 20268-KCurrent reportRegulation FD disclosure
- May 26, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Directors or officers changed · Regulation FD disclosure
- Apr 30, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportDirectors or officers changed
Official filings of Cartesian Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-143 M
- Net income
- $-130 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $296 M
- Total liabilities
- $423 M
- Total equity
- $-126 M
As of December-2025
Top 100 institutional investors in Cartesian Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Squarepoint Ops LLC | 2,263,230 | +8,611 (+0.38%) | 7.42% | $16 M | Nov 9, 2026 |
| 2 | BlackRock, Inc. | 808,458 | -10,781 (-1.32%) | 2.65% | $6 M | Nov 13, 2026 |
| 3 | 683 Capital Management, LLC | 751,000 | +101,000 (+15.54%) | 2.46% | $5 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 555,823 | 0 (0.00%) | 1.82% | $4 M | Nov 13, 2026 |
| 5 | FMR LLC | 370,457 | +2,028 (+0.55%) | 1.21% | $3 M | Nov 10, 2026 |
| 6 | Two Sigma Investments, LP | 367,350 | +71,057 (+23.98%) | 1.20% | $3 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 342,829 | -13,696 (-3.84%) | 1.12% | $2 M | Nov 6, 2026 |
| 8 | AQR Capital Management LLC | 287,156 | -69,300 (-19.44%) | 0.94% | $2 M | Nov 16, 2026 |
| 9 | State Street Corp | 261,736 | +12,524 (+5.03%) | 0.86% | $2 M | Nov 12, 2026 |
| 10 | Marshall Wace, LLP | 243,545 | +10,626 (+4.56%) | 0.80% | $2 M | Nov 13, 2026 |
| 11 | Millennium Management LLC | 221,858 | -88,029 (-28.41%) | 0.73% | $2 M | Nov 16, 2026 |
| 12 | UBS Group AG | 207,393 | -1,254 (-0.60%) | 0.68% | $1 M | Nov 10, 2026 |
| 13 | Janus Henderson Group Ltd. | 206,554 | — | 0.68% | $1 M | Nov 16, 2026 |
| 14 | Privium Fund Management B.V. | 155,000 | +3,325 (+2.19%) | 0.51% | $1 M | Nov 3, 2026 |
| 15 | CM Management, LLC | 120,000 | +60,000 (+100.00%) | 0.39% | $1 M | Nov 12, 2026 |
| 16 | Northern Trust Corp | 104,985 | -713 (-0.67%) | 0.34% | $1 M | Nov 16, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 91,645 | -209 (-0.23%) | 0.30% | $1 M | Nov 13, 2026 |
| 18 | Vanguard Portfolio Management LLC | 88,880 | +1,563 (+1.79%) | 0.29% | $1 M | Nov 13, 2026 |
| 19 | Trexquant Investment LP | 74,615 | +33,569 (+81.78%) | 0.24% | $1 M | Nov 16, 2026 |
| 20 | ADAR1 Capital Management, LLC | 73,877 | -25,000 (-25.28%) | 0.24% | $1 M | Nov 16, 2026 |
| 21 | Renaissance Technologies LLC | 72,200 | +51,900 (+255.67%) | 0.24% | $1 M | Nov 12, 2026 |
| 22 | Citadel Advisors LLC | 70,005 | New | 0.23% | $1 M | Nov 16, 2026 |
| 23 | Nuveen, LLC | 69,193 | +5,739 (+9.04%) | 0.23% | $0 M | Nov 10, 2026 |
| 24 | BNP Paribas Financial Markets | 65,754 | +1,777 (+2.78%) | 0.22% | $0 M | Nov 12, 2026 |
| 25 | Acadian Asset Management LLC | 63,266 | +35,520 (+128.02%) | 0.21% | $0 M | Nov 9, 2026 |
All 100 institutional investors: 26 to 100, with who bought and sold →
Mutual funds holding Cartesian Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 376,309 | $4 M | 1.2% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 338,605 | $4 M | 1.1% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 366,554 | $3 M | 1.2% | 0.05% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 169,730 | $2 M | 0.56% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 5.39 M | $2 M | — | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC | 195,163 | $2 M | 0.64% | 0.42% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 144,043 | $1 M | 0.47% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 94,871 | $1 M | 0.31% | <0.01% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 265,512 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 44,124 | $0 M | 0.14% | 0.03% | +70% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 57,254 | $0 M | 0.19% | <0.01% | −3.3% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 53,464 | $0 M | 0.18% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 32,500 | $0 M | 0.11% | 0.23% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.12 M | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 29,708 | $0 M | 0.10% | <0.01% | +69% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 32,118 | $0 M | 0.11% | <0.01% | +29% | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 22,160 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 21,239 | $0 M | 0.07% | 0.04% | +31% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 17,053 | $0 M | 0.06% | <0.01% | +6.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 16,271 | $0 M | 0.05% | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 555,522 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 59,796 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 17,320 | $0 M | 0.06% | <0.01% | +29% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 12,395 | $0 M | 0.04% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 16,604 | $0 M | 0.05% | <0.01% | +10% | May 31, 2026 |
As of Jul 31, 2026
Insider trading at Cartesian Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Elizabeth Hoge10% owner | Option exerciseindirect | +758,001 | — | — | 5.31 M | Form 4 |
| filed | Murat Kalayoglu10% owner | Option exerciseindirect | +758,001 | — | — | 5.31 M | Form 4 |
| filed | Michael SingerDirector | Gift | -6,555 | — | — | 49,578 | Form 4 |
| filed | Blaine DavisChief Financial Officer | Sell | -10,591 | $6.820 | $72 K | 121,220 | Form 4 |
| filed | Milos MiljkovicChief Medical Officer | Sell | -3,573 | $6.820 | $24 K | 58,820 | Form 4 |
| filed | Carsten BrunnPresident and CEO, Director | Sell | -23,766 | $6.820 | $162 K | 323,530 | Form 4 |
| filed | Michael SingerDirector | Grant or award | +2,600 | — | — | 56,133 | Form 4 |
| filed | Patrick J. ZennerDirector | Grant or award | +2,600 | — | — | 12,974 | Form 4 |
Markets and events: Cartesian Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-30.03 reverse split ; 3.9-for-1 split
Trading halts
- 2026-06-09 13:35 UTC, code LUDP, resumed 13:40 UTC
Fails to deliver
- : 1,641 shares at $6.28
- : 8,768 shares at $6.08
- : 945 shares at $6.27
- : 1,732 shares at $6.68
- : 1,289 shares at $7.36
Cartesian Therapeutics, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation0 of 4
Growth0 of 2
Profitability0 of 2
Financial health2 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cartesian Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2.8 | 39 | 26 | 111 | 85 | 17 | 6.7 | 0.9 | 0.2 | 8.1 | |
| Research and development | 58 | 45 | 71r | 72 | 69 | 55 | 43 | 48 | 45 | 30 | |
| General and administrative | 31 | 30 | 40r | 24 | 21 | 19 | 16 | 18 | 19 | 13 | |
| Operating expenses | 146 | 83 | 112 | 96 | 90 | 73 | 59 | 66 | 64 | 43 | |
| Operating income | −143 | −44 | −86 | 15 | −4.6 | −57 | −52 | −65 | −64 | −35 | |
| Interest and finance income | 6.6 | 7.4 | 5.0 | — | — | — | — | — | — | — | |
| Interest expense and finance costs | — | 0 | 2.8 | 3.0 | 2.8 | 1.6 | 1.5 | 1.5 | 1.2 | 1.3 | |
| Other non-operating income (expense) | 3.9 | −33r | 0.7 | 0.3 | 0.0 | 0.1 | −1.3 | 0.0 | −0.2 | 0.0 | |
| Income before tax | −139 | −77 | −239 | 35 | −9.7 | −69 | −55 | — | — | — | |
| Income tax | −9.2 | 0.3 | −19 | −0.6 | 16 | 0 | 0 | — | — | — | |
| Net income attributable to shareholders | −130 | −77 | −220 | 35 | −26 | −69 | −55 | −65 | −65 | −36 | |
| Earnings per share, basic | -5.02 | -4.48 | -49.76r | 0.24 | -0.22 | -0.68 | -1.22 | -2.92 | -3.20 | -3.89 | |
| Earnings per share, diluted | -5.02 | -4.49 | -49.76r | 0.10 | -0.22 | -0.68 | -1.22 | -2.92 | -3.20 | -3.89 | |
| Shares, weighted average (basic) | 26 | 17 | 5.2r | 145 | 114 | 101 | 46 | — | — | — | |
| Shares, weighted average (diluted) | 26 | 17 | 5.2r | 146 | 114 | 101 | 46 | 22 | 20 | 10 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 125 | 213 | 77 | 106 | 114r | 139 | 90 | 37 | 71 | 59 | |
| Short-term investments | — | — | 0 | 28 | 14 | 0 | — | 0 | 26 | 25 | |
| Receivables | 1.1 | 0.9 | 5.9 | 6.6 | 9.9 | 7.2 | 5.0 | 0 | 0.1 | 0.2 | |
| Other current assets | 3.0 | 3.1 | 5.0 | 3.8 | 6.5 | 5.4 | 1.5 | 0.1 | 2.0r | 2.4 | |
| Current assets | 129 | 217 | 91 | 148 | 144 | 151 | 97 | 42 | 99 | 87 | |
| Property, plant and equipment | 12 | 9.9 | 2.1 | 2.8 | 2.1 | 1.4 | 1.2 | 2.1 | 2.1 | 2.0 | |
| Right-of-use (leased) assets | 5.6 | 5.5 | 10 | 12 | 9.8 | 11 | 0.3 | — | — | — | |
| Goodwill | 48 | 48 | 48 | 0 | — | — | — | — | — | — | |
| Total assets | 296 | 435 | 305 | 166 | 160 | 165 | 100 | 44 | 101 | 89 | |
| Accounts payable | 1.3 | 0.3 | 3.2 | 0.3 | 0.2 | 0.4 | 0.5 | 1.1 | 1.6 | 3.9 | |
| Current liabilities | 15 | 23 | 68 | 25 | 72 | 82 | 35 | 35 | 11 | 14 | |
| Long-term debt | 0 | — | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 8.5 | 11 | 8.8 | 10 | 8.6 | 9.6 | 0 | — | — | — | |
| Total liabilities | 423 | 442 | 445 | 72 | 137 | 183 | 91 | 50 | 49 | 34 | |
| Retained earnings | −822 | −692 | −615 | −395 | −430 | −405 | −336 | −280 | −217 | −152 | |
| Shareholders' equity | −126 | −6.8 | −440 | 94 | 23 | −18 | 8.4 | −5.4 | 52 | 55 | |
| Total liabilities and equity | 296 | 435 | 305 | 166 | 160 | 165 | 100 | 44 | 101 | 89 | |
| Shares outstanding | 26 | 26 | 5.4r | 153 | 124 | 108 | 86 | 22 | 22 | 18 | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 11 | 6.6 | 23 | 11 | 7.7 | 5.4 | 5.2 | 5.7 | 4.1 | 2.1 | |
| Cash from operating activities | −74 | −24 | −51 | −32 | −60 | 35 | −51 | −59 | −52r | −20r | |
| Capital expenditure | −5.5 | −9.1 | −0.2 | −1.2 | −1.1 | −0.8 | −0.0 | −0.9 | −0.7 | −0.6 | |
| Cash from investing activities | −5.5 | −8.7 | 35 | −15 | −17 | −0.7 | 0.2 | 25 | −2.1 | −22 | |
| Debt issued | — | — | — | 0 | 0 | 25 | 0 | 0 | — | — | |
| Debt repaid | — | 0 | −27 | 0 | 0 | −19 | −2.8 | 0 | −13 | 0 | |
| Shares issued | — | — | — | 2.1 | 52 | 2.1 | 31 | 0 | 10 | 2.7 | |
| Cash from financing activities | −8.1 | 168 | −13 | 39 | 53 | 14 | 105 | 0.7 | 66 | 68 | |
| Exchange-rate effect on cash | 0.0 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | 0.0 | −0.2 | 0.1 | 0.5 | |
| Change in cash | −87 | 136 | −30 | −7.4 | −25 | 49 | 54 | −33 | 12r | 26r | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
What Cartesian Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Operating$3 M100%-93%
As of Dec 31, 2025
Where Cartesian Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
Executive pay at Cartesian Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Brunn | $4.3 M | −$634 K | $2.0 M | $25 |
| 2024Dr. Brunn | $7.3 M | $6.5 M | $2.8 M | $61 |
| 2023Dr. Brunn | $6.1 M | $6.4 M | $1.8 M | $70 |
As of Dec 31, 2025
Events at Cartesian Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
As of Nov 5, 2026
Acquisitions and funding#
1 acquisitions, $169 M paid where reported · 8 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Old Cartesian | 2023 | — | $169 M | 100% | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2024 | $130 M | Private placement after listing | $50 to $250 million | 22 | equity | SEC |
| Jul 2020 | $25 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Dec 2019 | $70 M | Private placement after listing | $50 to $250 million | 26 | equity, options | SEC |
| Aug 2019 | $6 M | Private placement after listing | $2 to $10 million | 10 | equity | SEC |
| Jun 2017 | $50 M | Private placement after listing | $50 to $250 million | 11 | equity, options | SEC |
| Dec 2016 | $5 M | No. 8 | $2 to $10 million | 1 | equity | SEC |
| Aug 2015 | $37 M | No. 7 | $10 to $50 million | 19 | equity, options | SEC |
| Apr 2015 | $6 M | No. 6 | $2 to $10 million | 12 | debt, options | SEC |
| Aug 2014 | $4 M | No. 5 | $2 to $10 million | 11 | equity | SEC |
| Jul 2014 | $6 M | No. 4 | $2 to $10 million | 2 | equity | SEC |
| Apr 2014 | $5 M | No. 3 | $2 to $10 million | 11 | equity | SEC |
| Nov 2011 | $22 M | No. 2 | $10 to $50 million | 16 | equity | SEC |
| Mar 2010 | $15 M | No. 1 | $10 to $50 million | 14 | equity | SEC |
H-1B hiring at Cartesian Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $73 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Quality Control SpecialistMolecular and Cellular Biologists | 1 | $73 K |
Where: Gaithersburg, MD 1
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 36% of workforce | Restructuring planSEC 8-K | “(“Selecta” or the “Company”) approved a plan to reduce Selecta’s headcount by approximately 36% (the “Workforce Reduction”) following a strategic review of the Company’s business.” | Filing |
How Cartesian Therapeutics, Inc. compares in Biotechnology
- Market cap$192 M · higher than 44% of 732
- Revenue growth49.6% · higher than 72% of 441
- FCF yield-41.4% · higher than 27% of 456
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cartesian Therapeutics, Inc.🇺🇸 | $192 M | — | — | +49.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
How current the figures are
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cartesian Therapeutics, Inc.? Verify and update this profile — free
Show Cartesian Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.